vinblastine / Generic mfg. - LARVOL DELTA

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers. (PubMed, Eur J Haematol) - P | "BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. In Ya&A with high-risk cHL, our data suggest that a BV-driven strategy (without bleomycin and consolidation radiotherapy) is an effective up-front option in oncologic centers specialized in HL care, improving the rate of durable complete remission in routine clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT06857500."

Journal • Cardiovascular • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain

The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL) (ASH 2025) - "We assessed PROs in S1826, a trial showingthat nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) resulted in longer progression-free survival compared to brentuximab vedotin plus AVD (BV+AVD). Trial results support the feasibility ofserial collection of PROs, as indicated by high response rates, despite participants' advanced stagedisease and broad institutional participation. Future analyses will address the planned 3-year outcomesas well as formal evaluation of missing data."

Clinical • Metastases • P3 data • Patient reported outcomes • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study (ASTRO 2025) - "16 (89%) received doxorubicin/hydroxydaunorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), 12 (67%) with <6 cycles...Subsequent treatment for the three patients currently in remission included pembro plus gemcitabine/vinorelbine/liposomal doxorubicin followed by ASCT (n=1), brentuximab vedotin (BV) plus nivolumab followed by ASCT (n=1) and 2 doses of BV followed by additional RT (n=1)... Pembro-RT yielded excellent CMR rates and minimal toxicity. These data suggest pembro-RT as a potential alternative to high dose chemo and SCT in localized, favorable relapsed/refractory HL. Enrollment to the study is complete and data will be updated prior to the meeting."

Clinical • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma (ASH 2025) - "Introduction: The randomized phase 3 S1826 study demonstrated that, in adolescent and adult patients(pts) with previously untreated advanced stage (AS) classic Hodgkin lymphoma (cHL), PD-1 blockade withnivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) prolongedprogression-free survival (PFS) compared with standard brentuximab vedotin (BV) combined with AVD ata median follow-up of 2 years. The benefit of N-AVD compared to BV-AVD in adolescent and adult pts with AS cHL issustained with 3y follow-up, including all pre-specified age, stage, and IPS risk subgroups. This updatedemonstrates the durability of remissions with N-AVD over time without any new safety signals, andenables benchmarking with other modern cHL trials. Follow-up will continue to evaluate for latetoxicities, OS, and PROs."

Metastases • Classical Hodgkin Lymphoma • Genetic Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Skin Cancer • Solid Tumor

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma. (PubMed, Blood) - P2 | "Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with non-bulky, early-stage cHL. ClinicalTrials.gov: NCT03646123."

Journal • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology

PRESENTATION OF PATIENT WITH NEUROFIBROMATOSIS I, DUCHENNE MUSCULAR DYSTOPHY, AND GLIOMATOSIS CEREBRI (WRMC 2026) - "He was started on chronic treatment with 5mg/5mL prednisone. We report a case of a 13 year old male who presented at 21 months of age for evaluation of macrocephaly, multiple café-au-lait macules, global developmental delay, and motor delay. The patient was diagnosed with neurofibromatosis type 1 (NF1) with left cervical spine and left hemipelvis plexiform neurofibroma. Despite physical therapy, the patient had persistent generalized hypotonia, more pronounced in his lower extremities."

Clinical • Brain Cancer • Developmental Disorders • Duchenne Muscular Dystrophy • Genetic Disorders • Muscular Dystrophy • Neurofibromatosis • Palliative care • Solid Tumor • NF1

2-YEAR FOLLOW-UP OF THE S1826 STUDY CONFIRMS IMPROVED PROGRESSION-FREE SURVIVAL WITH NIVOLUMAB-AVD COMPARED TO BRENTUXIMAB VEDOTIN-AVD IN ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA (ISHL 2024) - "We hypothesized that introducing PD-1 blockade with nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) would improve progression-free survival (PFS) over BV-AVD in AS cHL and evaluated this approach in the randomized, phase 3 S1826 study. N-AVD was better tolerated and improved PFS versus BV-AVD in adolescent and adult pts with AS cHL. Longer follow-up confirmed the PFS benefit with N-AVD at 2 y, including pre-specified subgroups. N-AVD is a new standard of care for treatment of AS cHL."

Metastases • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Pediatrics • Pneumonia

Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors (clinicaltrials.gov) - P1/2 | N=63 | Active, not recruiting | Sponsor: Centre Oscar Lambret | Trial primary completion date: May 2025 ➔ Dec 2025

IO biomarker • Trial primary completion date • Brain Cancer • Ependymoma • Pediatrics • Solid Tumor

Low-Dose Nivolumab Plus AVD As Front-Line Therapy for Classical Hodgkin's Lymphoma: Preliminary Results of a Phase 2 Trial (ASH 2024) - P2 | "Objective : We aimed to evaluate the safety and efficacy of low-dose nivolumab in combination with AVD (doxorubicin, vinblastine and dacarbazine) as a first-line treatment for cHL. After two cycles, all patients achieved an objective response, with most attaining a complete metabolic response and continuing with AVD alone. This approach presents a potential strategy for improved treatment efficacy while mitigating financial and biological toxicity, especially in LMICs."

P2 data • Classical Hodgkin Lymphoma • Endocrine Disorders • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • PD-1

The Management of older patients with Hodgkin lymphoma: implications of S1826. (PubMed, Semin Hematol) - P3 | "A recent phase 3 clinical trial (S1826, NCT03907488) led by the North American oncology cooperative groups compared brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) with nivolumab, doxorubicin, vinblastine, and dacarbazine (N-AVD). As a result, N-AVD is poised to become a standard of care for older, advanced-stage cHL patients who are fit for full-dose anthracycline-based combination therapy. More studies are needed to continue to improve outcomes for older cHL patients, especially unfit and frail populations."

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pain

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study (ASH 2023) - P2 | "Introduction: Brentuximab vedotin (BV) is an antibody-drug conjugate approved for multiple cancer types, including previously untreated stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine (AVD) in adults. The use of 2 active, targeted agents with distinct and complementary mechanisms of action for the frontline treatment of advanced stage cHL resulted in promising efficacy, safety, and tolerability. These results demonstrate continued tolerability of AN+AD with no new safety signals observed. AN+AD may provide a future first-line treatment option for patients with advanced stage cHL; long-term follow-up is ongoing."

Clinical • Metastases • P2 data • Classical Hodgkin Lymphoma • Endocrine Disorders • Fatigue • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Septic Shock

Updated Analysis of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Nonbulky, Early-Stage Classical Hodgkin Lymphoma (ASH 2024) - P2 | "Conclusions This updated analysis from the SGN35-027 part C study demonstrated continued efficacy of this novel regimen, sparing bleomycin, vinblastine, and radiation, in early-stage cHL, with a CR rate of 92% and 36-month PFS rate of 95%. The safety profile remains favorable and consistent with that in the prior analysis. Long-term results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with nonbulky, early-stage cHL."

Classical Hodgkin Lymphoma • Endocrine Disorders • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pneumonia

PHASE 2 TRIAL OF NIVOLUMAB PLUS ADRIAMYCIN, VINBLASTINE, DACARBAZINE (N-AVD) AS FRONTLINE THERAPY IN OLDER ADULTS WITH HODGKIN LYMPHOMA (ICML 2023) - "The research was funded by: Bristol Myers Squibb Background: Outcomes of classical Hodgkin lymphoma (cHL) remain poor in older adults (OA) with 5- year progression free survival (PFS) of 60% even with curative therapy (Cheng, et al. N-AVD is a highly effective and well tolerated frontline regimen in older adults with cHL. With no upper age, the phase 3 Intergroup study comparing N-AVD with brentuximab-AVD that recently completed accrual will provide definitive data on whether N-AVD will become a standard of care regimen in pts with newly diagnosed cHL."

Clinical • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

5-YEAR UPDATE ON FRONTLINE BRENTUXIMAB VEDOTIN WITH AVD FOR STAGE II-IV HIV-ASSOCIATED CLASSICAL HODGKIN LYMPHOMA (AMC-085) (ICML 2025) - P1/2 | "Research funding declaration: National Institute of Health/National Cancer Institute UM1CA121947 and UM1CA181255 Background: In the phase 3 ECHELON-1 (E1) study, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) significantly improved modified progression-free survival (PFS) and 6 year OS in patients (pts) with newly-diagnosed Stage III/IV Hodgkin lymphoma (cHL) compared to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Persons with HIV (PWH) were excluded from all prior BV clinical trials, and subsequently only 5 PWH received BV-AVD in the phase III S1826 study BV-AVD versus nivolumab-AVD... With a median follow-up of 67 months, stage II-IV HIV-cHL treated with BV-AVD enjoyed a PFS and OS of 78 and 89% respectively, with all events occurring within 3 years of enrollment. Neuropathy resolved to baseline in 83% of patients similar to the non-HIV BV-AVD studies. Compared to historical controls, PFS and OS appear similar to the..."

Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced-Stage Classical Hodgkin Lymphoma. (PubMed, Blood) - P2 | "Recent data on combining brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine demonstrated improved overall survival compared to ABVD but increased adverse events (AEs). Further evaluation of programmed death receptor 1 inhibitor and CD30 antibody-drug conjugate combination regimens in frontline advanced stage cHL is warranted. Trial registration: NCT03646123."

Clinical • Journal • Metastases • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain • TNFRSF8

AN ABBREVIATED COURSE OF A+AVD FOLLOWED BY NIVOLUMAB CONSOLIDATION FOR FRONTLINE THERAPY IN PATIENTS WITH LIMITED STAGE HODGKIN LYMPHOMA (EHA 2024) - P2 | "Based on the established efficacy of brentuximab vedotin (BV) andnivolumab (NVB) in HL, we hypothesized that a short course of A+AVD (BV, doxorubicin, vinblastine,dacarbazine) and NVB consolidation can supplant ABVD and RT, respectively, leading to improvedprogression-free survival (PFS) without excess treatment-related mortality or morbidity in patients with limitedstage non-bulky HL. ACCRU-LY1601 is the largest study with the longest follow-up reported to date to incorporate two novelagents (BV and NVB) in patients with previously untreated limited stage HL, representing a novel strategyaimed to obviate the need for dose-escalated chemotherapy and RT. As expected, a short course of A+AVDappeared to have more favorable safety profiles compared to the setting where an extended course (i. e."

Clinical • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Metabolic Disorders • Neutropenia • Oncology • Pain

A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2). (ASCO-GU 2025) - P2 | " This is a phase II, multi-institutional trial in which pts with cT2-T3N0M0 MIBC, ECOG PS 0-1 and CrCl≥50 mL/min received neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) with nivolumab. Interim results of RETAIN-2 show a 46% pT0 rate in those allocated to cystectomy and a 78% metastasis-free bladder-preservation rate in those allocated to AS. Follow-up is ongoing for the primary endpoint of 2-year MFS."

Clinical • IO biomarker • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • ERCC2 • RB1

SERUM TARC DYNAMICS CORRELATE WITH CLINICAL RESPONSE AND METABOLIC TUMOR VOLUME DURING ANTI-PD1-BASED FIRST-LINE HL TREATMENT IN THE GHSG PHASE II NIVAHL TRIAL (ISHL 2024) - P2 | "To our knowledge, this is the first study correlating TARC dynamics with metabolic tumor volume (MTV) and clinical response during either sequential or concomitant nivolumab and doxorubicin, vinblastine, and dacarbazine (N-AVD) first-line treatment of early-stage unfavorable cHL patients. Patients in the prospective randomized GHSG NIVAHL phase II trial were evaluated for early treatment response (RE2) after 2× N-AVD (arm A) or four nivolumab (N) infusions (arm B), respectively (NCT03004833). Serum TARC levels correlate with MTV and treatment response in cHL patients receiving anti-PD1-based first-line treatment. Importantly, TARC negativity is achieved very early also during nivolumab monotherapy and associated with excellent outcomes despite interim or end-of-treatment PET positivity."

Clinical • IO biomarker • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma. (PubMed, J Clin Oncol) - P1/2 | "N-AVD is a highly effective and well-tolerated frontline regimen in OA with cHL across a wide range of geriatric impairments."

Journal • P2 data • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology

HEALTH-RELATED QUALITY OF LIFE (HRQoL) ENDPOINTS OF THE PHASE III INTERGROUP S1826 ADVANCED-STAGE, CLASSIC HODGKIN LYMPHOMA (cHL) TRIAL (ICML 2025) - "We assessed HRQoL in S1826, a trial showing that nivolumab plus doxorubicin, vinblastine, and dacarbazine (N+AVD) resulted in longer progression-free survival compared to brentuximab vedotin plus AVD (BV+AVD). Despite advanced stage disease and intensive treatment, completion rates of HRQoL assessments were high and did not differ by participant age (data not shown). Worse fatigue was found at the EOT, and less neuropathy throughout year 1, for patients on the N+AVD arm, whereas worse neuropathy was found in the BV-AVD arm at all specified time points. Further analyses are planned to evaluate the effect of these treatments on global HRQoL and further understand the impact of participant age and completion rates/retention on between-arm differences."

Clinical • HEOR • Metastases • P3 data • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part B) (ASH 2022) - P2 | "Introduction Brentuximab vedotin (BV) and nivolumab are well tolerated and active treatments for patients (pts) with classical Hodgkin lymphoma (cHL). Omitting bleomycin and vinblastine may have contributed to the absence of certain AEs, such as febrile neutropenia. This study is ongoing and updated results will be presented."

Clinical • P2 data • Endocrine Disorders • Fatigue • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immune Modulation • Inflammation • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pain • Pneumonia

Pembrolizumab and Involved Site Radiation Therapy Alone As an Alternative to Transplant in Patients with Localized Failure Following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study (ASH 2024) - "16 (89%) received adriamycin/bleomycin/vinblastine/dacarbazine (ABVD), 12 (67%) with <6 cycles...Subsequent treatment for the 3 patients currently in remission included pembrolizumab plus gemcitabine/vinorelbine/liposomal doxorubicin followed by ASCT (n=1), brentuximab vedotin (BV) plus nivolumab followed by ASCT (n=1) and 2 doses of BV followed by additional RT (n=1).Immune-related toxicities were 3 (17%) grade 1 rash, and 2 (12%) grade 2 hypo/hyperthyroidism...These data suggest pembrolizumab-RT as a potential alternative to high dose chemotherapy and ASCT in localized, favorable relapsed/refractory HL. Enrollment to the study continues."

Clinical • P2 data • Endocrine Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Transplantation

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma (ASH 2024) - P1/2 | "While historical data have supported ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) treatment without granulocyte-colony stimulating factor (G-CSF) despite neutropenia, management in CPI-based combinations is currently undefined...Conclusion Compared to combination nivolumab and AVD, rates of grade 4 neutropenia were high at 70% in patients treated with APVD. Rates of primary and secondary prophylaxis with G-CSF were low. Despite higher rates of neutropenia, FN and grade ≥3 infections were uncommon and appeared similar to historical data with ABVD."

Clinical • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Oncology • Septic Shock

FIVE-YEAR FOLLOW-UP OF NIVOLUMAB-BASED COMBINATIONS AND TRANSPLANT STRATEGY AFTER PD-1 INHIBITOR FAILURE IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (EBMT 2026) - "All patients were treated with combination of nivo (3 mg/kg or 40 mg every 2 weeks) and chemo- or targeted therapy: bendamustine 90 mg/m² D1,2 of a 28-day cycle (n=55), vinblastine 10 mg every 2 weeks (n=42), brentuximab vedotin (BV) 1.8 mg/kg every 3 weeks (n=20), or gemcitabine 800-1000 mg every 2 weeks (n=6). The use of combination regimens with CPI represents an effective and safe strategy. This approach is beneficial for patients who have failed multiple therapy lines including CPI, including its use as a bridge to allo-HCT, as well as for patients who are not candidates for transplantation."

Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Transplantation